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Abstract In this paper, it is demonstrated that all-trans, 9-cis
and 13-cis retinoic acid (RA) decreased the sensitivity of SK-N-
BE(2)c neuroblastoma cells towards the chemotherapeutic agent
cyclopentenyl cytosine (CPEC), a potent inhibitor of cytosine-
5P-triphosphate synthetase. Retinoic acid attenuated CPEC-in-
duced apoptosis as re£ected by a decreased caspase-3 induction.
Retinoic acid decreased the accumulation of CPEC, whereas the
salvage of cytidine was strongly increased. Metabolic labeling
studies using [3H]uridine showed a strongly decreased biosyn-
thesis of CTP via CTP synthetase. Retinoic acid likely confers
resistance of neuroblastoma cells to CPEC in part by slowing
down proliferation, and in part by shifting the synthesis of CTP
towards the salvage of cytidine, thereby bypassing CTP
synthetase. 1 2002 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
Neuroblastoma is the most common extra cranial solid tu-
mor of childhood. The tumors are derived from the neural
crest and originate where nervous tissue is present. The dis-
ease has ¢ve distinct prognostic stages, stages 1^4 and 4S.
Despite considerable research, the prognosis for patients suf-
fering from stage 4 neuroblastoma, which is characterized by
disseminated disease, is still very poor [1]. Stage 4S neuro-
blastoma, however, is able to di¡erentiate into more mature
forms and has a high rate of spontaneous regression [2,3].
This spontaneous di¡erentiation of neuroblastoma cells has
triggered a great deal of research focused on the induction
of di¡erentiation of neuroblastoma in vivo. Both in vitro
and in vivo, neuroblastoma cells can be induced to di¡eren-
tiate by all-trans retinoic acid (ATRA) and its conformational
isomers 9-cis retinoic acid (9-cis RA) and 13-cis retinoic acid
(13-cis RA) [4,5]. Clinical trials studying the e¡ects of ATRA
and 13-cis RA in the treatment of disseminated neuroblasto-
ma indicate a clinical response in some patients [6^11]. Of the
retinoic acid isomers 9-cis RA has been reported to have the
strongest di¡erentiation inducing e¡ect in several cell line sys-
tems [12^14]. Furthermore, ATRA has been shown to be iso-
merized partly to 9-cis RA in liver [15,16]. Hence, 9-cis RA
may be tested in clinical settings as well as ATRA and 13-cis
RA.
To date, little is known about the e¡ect of di¡erentiating
agents on the e⁄cacy of cytostatic nucleoside analogues in
neuroblastoma. Results from clinical trials in which patients
su¡ering from leukemia were treated with ATRA and cytar-
abine, an analog of deoxycytidine, showed a synergistic e¡ect
when ATRA and cytarabine were combined [17^19]. In this
study, we studied the e¡ect of ATRA, 9-cis RA and 13-cis RA
on the cytotoxicity and metabolism of cyclopentenyl cytosine
(CPEC) as well as pyrimidine nucleotide biosynthesis in neu-
roblastoma cells. CPEC is a pro-drug that in its nucleoside
triphosphate form (CPECTP) potently inhibits cytosine-5P-tri-
phosphate (CTP) synthetase, causing depletion of cytidine
nucleotides [20]. We have previously shown that CPEC, as
single agent, has profound and long lasting cytostatic e¡ects
on human neuroblastoma cells in vitro [21]. In this paper we
demonstrate that retinoic acid to a large extent attenuates the
cytostatic e¡ect of CPEC.
2. Materials and methods
2.1. Chemicals
CPEC (NSC 375575) was obtained from the Developmental Ther-
apeutics Program, NCI (Division of Cancer Treatment, National Can-
cer Institute, MD, USA). ATRA, 13-cis RA, 9-cis RA and all nucle-
otide standards were obtained from Sigma-Aldrich Chemie
(Zwijndrecht, The Netherlands). [14C-U]uridine (18.6 GBq/mmol)
and [14C-cytosine]cytidine (2.04 GBq/mmol) were obtained from
Amersham International (Buckinghamshire, UK). Nonidet P40 was
obtained from LKB-produkter AB (Bromma, Sweden). Dulbecco’s
modi¢ed Eagle’s medium (DMEM), bovine fetal serum and penicil-
lin/streptomycin/fungizone mix were obtained from BioWhittaker Eu-
rope (Verviers, Belgium). L-Glutamine and gentamicin were obtained
from Gibco BRL (Paisly, UK). All other chemicals were of analytical
grade.
2.2. Cell culture
The SK-N-BE(2)c neuroblastoma cell line was obtained from the
American Type Culture Collection. The cells were routinely cultured
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in DMEM, supplemented with 2 mM L-glutamine, 50 IU/ml penicil-
lin, 50 Wg/ml streptomycin, 0.2 mg/ml gentamicin, 0.25 Wg/ml fungi-
zone and 10% v/v bovine fetal serum at 37‡C in humidi¢ed air with
5% CO2. The cells were maintained in 75 cm2 loosely capped culture
£asks (Co-star Corp.) and maintained in logarithmic growth phase.
SK-N-BE(2)c was used up to passage 45. Di¡erentiated cells were
obtained by incubation with ATRA (100 nM for 6 days or 10 WM
for 2 days, resulting in the same degree of di¡erentiation). Cell cul-
tures were consistently free of mycoplasma (tested with Mycoplasma
PCR ELISA, Boehringer Mannheim, Mannheim, Germany).
2.3. Proliferation and di¡erentiation
Cells were seeded into 6-well plates (Corning Co-star) at a density
of 0.25^0.50U106 cells per well, and allowed to adhere overnight. The
experiments were started by replacing the medium with medium con-
taining the appropriate retinoic acid isomer in 0.1% ethanol. As a
control, the proliferation of cells in medium containing only 0.1%
ethanol was also measured. Adherent cells were harvested by trypsi-
nization and cell numbers were determined after solubilizing the cells
in isoton II containing 2.7U1037% (v/v) Triton X-100 and
2.7U1033% (w/v) saponin. The nuclei were counted with a Coulter
Counter Z 1000 with a 100 WM ori¢ce (Coulter Electronics Ltd, Buck-
inghamshire, UK). The viability of adherent cells was more than 99%,
as determined by exclusion of trypan blue.
To assess the degree of di¡erentiation induced by retinoic acid, 400
cells per culture per day were examined by microscopy. Cells with
neurites with a length of approximately twice the diameter of the
cell body were scored as being di¡erentiated, as well as cells that
were connected to one another by means of neurites.
2.4. Assay for drug sensitivity
Cells were plated in 24-well plates at a density of 30U103 cells per
well in a total volume of 0.5 ml. After overnight adherence, the me-
dium was changed for medium containing CPEC and/or retinoic acid.
In the case of pre-incubation with retinoic acid, cells were incubated
for 2 days with 100 nM retinoic acid, and subsequently harvested and
cultured in medium without retinoic acid in 24-well plates, as de-
scribed above. After the incubation time, the number of viable cells
was measured using the MTT assay as described previously [22] and
IC50 values were determined.
2.5. Nucleotide extraction and analysis
Cells were seeded in 6-well plates at a density of 0.25^1U106 cells
per well. After overnight adherence, the cells were incubated with 100
nM ATRA for 6 days or with 10 WM ATRA for 2 days. After in-
cubation with ATRA, the medium was changed with fresh medium
and subsequently CPEC was added to the culture medium. Control
cells, which were not pre-treated with ATRA, were incubated with
CPEC after overnight adherence. After 6 h incubation with CPEC,
the cells were washed once with phosphate-bu¡ered saline (PBS) and
extracted with perchloric acid and analyzed, as described previously
[21].
2.6. Extraction and analysis of radiolabeled nucleotides
Cells were seeded and pre-treated as described in Section 2.5. After
incubation with ATRA, the medium containing ATRA was removed
and replaced by medium spiked with 1.8 WM [14C]cytidine or 0.36 WM
[14C]uridine. The ¢nal concentrations (radiolabeled+endogenous nu-
cleosides) of cytidine and uridine in the medium were 2.0 WM and 1.8
WM, respectively. As a consequence, the speci¢c activity of the label
was corrected for the presence of the endogenous amounts of cytidine
and uridine. After 3 h, the cells were extracted with 0.4 M perchloric
acid and nucleotide pro¢les were determined by ion-exchange high
performance liquid chromatography (HPLC), as described previously
[21]. Radioactivity was detected online with a Radiomatic 525TR
Flow Scintillation Analyzer with a 500 Wl TR-LSC cell (Packard In-
strument, Meriden, CT, USA) using Ultima Flo AP (Packard, Dow-
ers Grove, IL, USA) at an e¥uent to scintillation £uid ratio of 1:1.
The acid precipitate was taken up in 300 Wl of 0.2 M NaOH and
precipitated again by adding an equal volume of 1.2 M perchloric
acid. The protein and DNA containing fraction was obtained by
centrifugation and dissolved in a ¢nal volume of 200 Wl 0.2 M
NaOH. An aliquot of the dissolved pellet was mixed with scintillation
£uid and the radioactivity was measured on a L-counter. The protein
content was determined using bicinchonic acid solution containing
0.1% CuSO4, as described previously [23].
2.7. CTP synthetase assay and calculation of the £ux through
CTP synthetase
The CTP synthetase activities in crude homogenates were deter-
mined as described previously [21,24].
From the distribution of the radiolabel after labeling with
[14C]uridine the £ux through CTP synthetase could be calculated.
The £ux through CTP synthetase was calculated using the following
ratio [14C]CTP/([14C]UDPG+[14C]UDPNAG+[14C]UTP+[14C]CTP).
2.8. Apoptosis
Apoptosis was detected by measuring caspase-3 activity using the
caspase-3 colorimetric assay of RpD Systems (Oxon, UK). The assay
was performed according to the manufacturer’s manual, except that
after lysis of the cells (2U106 cells per 50 Wl), the cell lysates were
centrifuged for 5 min at 18 620Ug at 4‡C. The caspase-3 activity is
expressed relative to that observed in untreated control cells. The
caspase-3 activities of the various cultures that had been treated
with CPEC, ATRA or the combination were analyzed with the
t-test for paired samples, using the MS Excel software package. A
P-value 6 0.05 was considered to be statistically signi¢cant.
3. Results
3.1. The e¡ect of retinoic acid on the proliferation and
induction of di¡erentiation of SK-N-BE(2)c cells
All three retinoic acid isomers inhibited the proliferation of
SK-N-BE(2)c neuroblastoma cells in a concentration-depen-
Fig. 1. The e¡ect of ATRA on the proliferation and di¡erentiation of SK-N-BE(2)c cells. A: The e¡ect of ATRA on proliferation. The results
shown are the mean of three experimentsWS.D. B: The induction of di¡erentiation by ATRA. The di¡erentiation index was assessed by micro-
scopically examination of 400 cells per culture per day. a 0.1% ethanol; b 1 nM ATRA; U 10 nM ATRA; E 100 nM ATRA; R 1 WM
ATRA.
FEBS 26460 29-8-02
J. Bierau et al./FEBS Letters 527 (2002) 229^233230
dent manner (Fig. 1A). The results obtained with ATRA were
also representative for the results obtained with 9-cis and 13-
cis RA. Proliferation was not strongly inhibited by retinoic
acid concentrations up to 100 nM ATRA, but was inhibited
strongly by 1 WM ATRA.
Retinoic acid had a strong di¡erentiation inducing e¡ect on
SK-N-BE(2)c cells (Fig. 1B). After 3 days of incubation with
1 nM ATRA 35% of the cell population was di¡erentiated.
However, when SK-N-BE(2)c cells were incubated with 10^
1000 nM ATRA for 3 days 65^80% of the cell population was
di¡erentiated. Apparently, di¡erentiation did not exclude pro-
liferation.
3.2. The e¡ect of retinoic acid on CPEC cytotoxicity
Treatment of SK-N-BE(2)c cells with retinoic acid followed
by incubation with CPEC attenuated the cytostatic e¡ect of
CPEC when compared to cells treated with CPEC only. After
pre-treatment of SK-N-BE(2)c cells with ATRA, 9-cis RA or
13-cis RA, the IC50 values were approximately 5 times higher
than SK-N-BE(2)c cells treated for 4 days with CPEC only
(50W 2 nM) (Table 1). The inhibitory e¡ect of retinoic acid on
the cytostatic e¡ect of CPEC was even greater when SK-N-
BE(2)c cells were co-incubated with CPEC and retinoic acid.
In that case, the IC50 values were at least 8^20-fold higher
when compared to SK-N-BE(2)c cells treated with merely
CPEC (Table 1).
3.3. The e¡ects of retinoic acid on CTP depletion and
CPECTP accumulation
The CTP depletion caused by incubating SK-N-BE(2)c cells
with CPEC was less in cells pre-treated for 6 days with 100
nM ATRA than in control cells (Fig. 2A). After 6 h of in-
cubation with 1 WM CPEC, the CTP concentration of ATRA-
treated cells was 26% of that of untreated cells whereas the
CTP content of control cells had dropped to 7% of the initial
value. Control cells accumulated more CPECTP than cells
that had been pre-incubated with 100 nM ATRA for 6 days
(Fig. 2B). After 6 h of incubation with 2.5 WM CPEC, control
SK-N-BE(2)c cells had accumulated twice the amount of
CPECTP when compared to SK-N-BE(2)c cells that had
been pre-treated with 100 nM ATRA for 6 days.
3.4. The e¡ect of retinoic acid on pyrimidine metabolism and
ribonucleotide triphosphate levels
The biosynthesis of CTP via CTP synthetase was less in
SK-N-BE(2)c cells that had been treated with ATRA than
in untreated control cells. The CTP synthetase activity in
crude cell homogenates of cells treated with 100 nM ATRA
for 6 days decreased from 16.6W 2.1 pmol CTP/mg protein/h
in control cells to 9.4 W 0.7 pmol CTP/mg protein/h in ATRA-
treated cells. The same trend was observed with higher con-
centrations of ATRA and shorter incubation periods (data
not shown). On the other hand, the salvage of pyrimidine
nucleosides was increased (Fig. 3). Both the accumulation of
cytosine nucleotides and incorporation into DNA of radio-
labeled cytidine increased 2-fold after treatment of SK-N-
BE(2)c cells for 2 days with 10 WM ATRA. When radiolabeled
uridine was used instead of radiolabeled cytidine, the accumu-
lation of metabolites and the incorporation of label into DNA
were, respectively, 1.6- and 1.4-fold higher in ATRA-treated
cells than in control cells. After 3 h incubation with 1.8 WM
[14C]uridine control cells contained 0.183W 0.010 pmol
{[14C]UDPG+[14C]UDPNAG}/Wg protein, 0.226W 0.020
pmol [14C]UTP/Wg protein and 0.0668W 0.080 pmol
[14C]CTP/Wg protein. SK-N-BE(2)c cells that had been treated
with 10 WM ATRA for 2 days prior to the labeling with
1.8 WM [14C]uridine contained 0.277W 0.020 pmol
{[14C]UDPG+[14C]UDPNAG}/Wg protein, 0.415W 0.036
pmol [14C]UTP/Wg protein and 0.070W 0.005 pmol [14C]CTP/
Wg protein. Thus, the £ux through CTP synthetase, calculated
as described in Section 2, was 0.14 in control cells and 0.09 in
Table 1
The e¡ect of retinoic acid on CPEC cytotoxicity
Pre-treatment IC50
(nM)
Co-treatment IC50
(nM)
Normal medium 50W 2 50W 2
ATRA 237W 55 400^1000
9-cis RA 253W 45 s 1000
13-cis RA 258W 58 s 1000
To assess the e¡ect of pre-treatment, cells were cultured in the pres-
ence of 100 nM ATRA, 9-cis RA or 13-cis and subsequently plated
in 24-well plates in the absence of retinoic acid. After overnight ad-
herence the medium was changed for medium containing CPEC and
the cells were incubated for 4 days. To assess the e¡ect of co-incu-
bation, cells were plated in 24-well plates and after overnight adher-
ence, the medium was changed for medium containing CPEC and
100 nM retinoic acid and the cells were incubated for 4 days. IC50
values ( W S.D., n=3) were determined using the MTT assay.
Fig. 2. CTP depletion and CPECTP accumulation before and after treatment of SK-N-BE(2)c cells with ATRA. Cells were incubated with
CPEC for 6 h and subsequently extracted and the intracellular CTP content (A) and CPECTP content (B) were determined. b control cells ; a
cells treated for 6 days with 100 nM ATRA. The values shown are the mean of three experiments W S.D. The CTP content of control cells was
3.6W 0.5 pmol CTP/Wg protein and of ATRA-treated cells was 2.8W 0.1 pmol CTP/Wg protein.
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cells that had been treated with 10 WM ATRA for 2 days.
Uridine and cytidine mono- and diphosphates were only
present in trace amounts. The contribution of CTP synthetase
to the biosynthesis of CTP was, therefore, decreased by 36%
in SK-N-BE(2)c cells treated with ATRA when compared to
untreated control cells.
No major changes in the total pools of UTP, CTP, ATP
and GTP were observed in cells that were treated with ATRA
(0.1^10 WM) for 2^6 days when compared to untreated cells.
3.5. The e¡ect of retinoic acid on CPEC-induced apoptosis
When SK-N-BE(2)c cells were incubated with 250 nM
CPEC for 3 days, a 2-fold increase in the caspase-3 activity
was observed as compared to untreated controls, re£ecting the
induction of apoptosis. Culturing the cells in the presence of
100 nM ATRA for 3 days did not induce caspase-3 activity.
Combined incubation of 100 nM ATRA and 250 nM CPEC
resulted in less caspase-3 activity (1.6-fold when compared to
controls) than incubation with 250 nM CPEC alone
(P=0.03). Pre-treatment with 100 nM ATRA for 2 days, fol-
lowed by 3 days of incubation with 250 nM CPEC resulted in
1.9-fold increase in caspase-3 activity when compared to con-
trols.
4. Discussion
We have previously shown that CPEC as a single agent has
profound and long lasting cytostatic e¡ects on human neuro-
blastoma cells in vitro [21]. In this paper, we demonstrate that
retinoic acid largely attenuates the cytostatic e¡ect of CPEC.
This is best illustrated by the 5^20-fold increase in the IC50
value for CPEC upon either co- or pre-incubation with reti-
noic acid.
Because all three isomers of retinoic acid had the same
e¡ect on the toxicity of CPEC, ATRA was used as the rep-
resentative compound in the metabolic studies. To some ex-
tent, the acquired resistance towards CPEC might be due to
decreased proliferation caused by retinoic acid. When prolif-
eration slows down or is arrested, de novo nucleotide metab-
olism is reduced and salvage metabolism upregulated [25]. In
such a situation, a drug targeted at de novo synthesis is likely
to become less cytotoxic.
Our metabolic studies demonstrated that cells pre-treated
with retinoic acid showed a decreased accumulation of
CPECTP, the e¡ective compound that inhibits CTP synthe-
tase [20], when compared to untreated control cells. A de-
creased uptake of CPEC would be in line with the fact that
a decreased expression of the nucleoside transporters, by
which CPEC is taken up by the cell, was observed in di¡er-
entiated neuroblastoma cells [26,27].
Although the accumulation of CPECTP was less in SK-N-
BE(2)c cells treated with ATRA, the depletion of CTP caused
by CPEC was still profound. Therefore, the decreased accu-
mulation of CPECTP was probably not the sole cause of the
resistance towards CPEC induced by retinoic acid. The £ux
through CTP synthetase of radiolabeled uridine was reduced
by 36% in ATRA-treated cells when compared to control
cells. This observation is in line with the fact that the CTP
synthetase activity in cell homogenates was 43% less in SK-N-
BE(2)c cells that had been treated with ATRA than in un-
treated SK-N-BE(2)c cells. The preferential salvage of cytidine
over uridine in ATRA-treated cells might allow the cells to
bypass at least partly the inhibition of CTP synthetase by
CPECTP. Previous studies have also shown a decreased con-
tribution of CTP synthetase in the biosynthesis of CTP in
di¡erentiated neuroblastoma and gastric cancer cells as com-
pared to their more primitive counterparts [28,29]. Thus, a less
signi¢cant role for the synthesis of CTP via CTP synthetase in
ATRA-treated cells and a relatively increased utilization of
cytidine nucleotides may contribute to the decreased sensitiv-
ity towards CPEC.
The resistance induced by retinoic acid towards CPEC-in-
duced apoptosis may partially be explained by induction of
di¡erentiation, which is paralleled by decreased induction of
apoptosis in ATRA-treated cells [30,31]. ATRA has been re-
ported to inhibit the response to apoptotic stimuli in neuro-
blastoma by several mechanisms such as suppression of the
cell death pathway by altered Bcl-2 expression and altered
tra⁄cking of the p53 protein [30^33].
In conclusion, we have shown that retinoic acid largely
blocks the cytostatic and apoptotic e¡ects of CPEC in SK-
N-BE(2)c neuroblastoma cells. Furthermore, retinoic acid in-
creased the salvage of uridine and cytidine and decreased the
contribution of CTP synthetase to the intracellular CTP pool.
Our ¢ndings may have clinical implications as they demon-
strate that the sequence of administration of drugs in a multi-
drug schedule plays a pivotal role. At present, retinoic acid is
being used for the treatment of patients su¡ering from neuro-
blastoma. In case of a relapse after treatment with retinoic
acid neuroblastoma cells might have become resistant to other
anti-metabolites than CPEC as well.
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